FDA Clears CT/NG Assays for Extragenital Testing
By LabMedica International staff writers Posted on 05 Jun 2019 |
Image: The Aptima Combo 2 detects and differentiates ribosomal RNA from Neisseria gonorrhoeae and Chlamydia trachomatis (Photo courtesy of Hologic).
Chlamydia trachomatis commonly known as chlamydia is a bacterium that can replicate only in human cells. It can manifest in various ways, including: trachoma, lymphogranuloma venereum, non-gonococcal urethritis, cervicitis, salpingitis, pelvic inflammatory disease.
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Infection may involve the genitals, mouth, or rectum. It has been estimated that there were 1.7 million cases of chlamydia and more than 500,000 cases of gonorrhea in the USA in 2017, and the number of cases is rising, as is drug-resistance.
The US Food and Drug Administration (FDA, Silver Springs, MD, USA) have announced that it has cleared assays for extragenital indications for chlamydia and gonorrhea testing. The FDA reviewed clinical data collected through a multi-site study of more than 2,500 patients in its evaluation of the devices. The study, which was coordinated by the Antibacterial Resistance Leadership Group, looked at the diagnostic accuracy of multiple commercially available nucleic acid amplification tests for detection of Neisseria gonorrhoeae and Chlamydia trachomatis from throat and rectal sites. The results of this study and other information reviewed by the FDA demonstrated that the Aptima Combo 2 Assay and the Xpert CT/NG for extragenital specimens are safe and effective for extragenital testing for chlamydia and gonorrhea.
The two assays, The Aptima Combo 2 and the Xpert CT/NG had previously only been cleared for testing of urine, vaginal, and endocervical samples. The Aptima Combo 2 assay is a target nucleic acid probe test that utilizes target capture for the qualitative detection and differentiation of ribosomal RNA from N. gonorrhoeae and C. trachomatis. The Cepheid Xpert CT/NG Assay, performed on the GeneXpert Instrument Systems, is a qualitative in vitro real-time PCR test for the automated and rapid detection and differentiation of genomic DNA from C. trachomatis and N. gonorrhoeae to aid in the diagnosis of chlamydial and/or gonorrheal uro¬genital disease.
Timothy Stenzel, MD, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health, said, “These two tests will fill an unmet public health need by allowing for more screening.”
Related Links:
US Food and Drug Administration
Gonorrhea is a sexually transmitted infection (STI) caused by the bacterium Neisseria gonorrhoeae. Infection may involve the genitals, mouth, or rectum. It has been estimated that there were 1.7 million cases of chlamydia and more than 500,000 cases of gonorrhea in the USA in 2017, and the number of cases is rising, as is drug-resistance.
The US Food and Drug Administration (FDA, Silver Springs, MD, USA) have announced that it has cleared assays for extragenital indications for chlamydia and gonorrhea testing. The FDA reviewed clinical data collected through a multi-site study of more than 2,500 patients in its evaluation of the devices. The study, which was coordinated by the Antibacterial Resistance Leadership Group, looked at the diagnostic accuracy of multiple commercially available nucleic acid amplification tests for detection of Neisseria gonorrhoeae and Chlamydia trachomatis from throat and rectal sites. The results of this study and other information reviewed by the FDA demonstrated that the Aptima Combo 2 Assay and the Xpert CT/NG for extragenital specimens are safe and effective for extragenital testing for chlamydia and gonorrhea.
The two assays, The Aptima Combo 2 and the Xpert CT/NG had previously only been cleared for testing of urine, vaginal, and endocervical samples. The Aptima Combo 2 assay is a target nucleic acid probe test that utilizes target capture for the qualitative detection and differentiation of ribosomal RNA from N. gonorrhoeae and C. trachomatis. The Cepheid Xpert CT/NG Assay, performed on the GeneXpert Instrument Systems, is a qualitative in vitro real-time PCR test for the automated and rapid detection and differentiation of genomic DNA from C. trachomatis and N. gonorrhoeae to aid in the diagnosis of chlamydial and/or gonorrheal uro¬genital disease.
Timothy Stenzel, MD, PhD, director of the Office of In Vitro Diagnostics and Radiological Health in the FDA's Center for Devices and Radiological Health, said, “These two tests will fill an unmet public health need by allowing for more screening.”
Related Links:
US Food and Drug Administration
Latest Microbiology News
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia
- Rapid AST Platform Provides Targeted Therapeutic Results Days Faster Than Current Standard of Care
- New Analysis Method Detects Pathogens in Blood Faster and More Accurately by Melting DNA